essential hypertension/nausea

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 41 rezilta yo

Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The antihypertensive effect of a new vasodilator with betablocking properties (SK & F 92657) was investigated in 10 patients with mild to moderate essential hypertension. After a mean treatment period of 26,5 weeks (6,5-49 weeks) blood pressure was significantly reduced, from 168 +/- 22/106 +/- 6

Antihypertensive efficacy, tolerance, and safety of long-term treatment with ramipril in patients with mild-to-moderate essential hypertension.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A total of 555 hypertensive patients took part in a 2-year multicenter, open-label study to determine the efficacy, tolerance, and safety of long-term therapy with ramipril. In the beginning, all patients were to receive 5 mg of ramipril/day. The dosage was then adjusted in accordance with response

Captopril in the treatment of mild essential hypertension.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1 Among 34 patients with mild essential hypertension treated for four weeks with captopril alone the blood pressure of 47% returned to normal. By the end of the fourth week chlorthalidone had been added to captopril in 18 of the patients; 15 then achieved normal blood pressure, and only three failed

Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To assess the efficacy and safety of once daily olmesartan medoxomil 20 mg in Indian patients with stage 1 essential hypertension. METHODS This was an open label, multicentre, real world observational postmarketing surveillance conducted in male and female patients (N=825), in age group of

Enalapril and enalapril-hydrochlorothiazide in the treatment of essential hypertension. The Enalapril-Hydrochlorothiazide in Essential Hypertension Canadian Working Group.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A total of 217 patients with essential hypertension were enrolled by 25 Canadian centers in this double-blind, parallel study to compare the efficacy and safety of enalapril administered alone or in combination with hydrochlorothiazide. After a 4-week placebo period, patients were given 10 mg of

A multi-centre general practice trial of a pindolol/clopamide combination ('Viskaldix') in essential hypertension.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A large, open, multi-centre study was carried out in general practice to evaluate the effectiveness and tolerance of a combination of 10 mg pindolol plus 5 mg clopamide, in single tablet form, in the treatment of patients with essential hypertension. Computer analysis of the records of 8989 patients

-Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension. This study was a multicenter and open trial and lasted 24 weeks. During 7 visits arterial blood pressure, heart rate, body

Effects of untreated preoperative essential hypertension on post-operative pain after major abdominal surgery.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Hypertension has been associated with hypoalgesia. This prospective study was designed to test the effects of untreated preoperative essential hypertension on post-operative pain intensity and morphine requirement after major abdominal surgery. METHODS Sixty subjects (30 untreated

[Efficiency and safety of ACE-inhibiting imidapril in patients with essential hypertension].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In a survey including 2224 patients with essential hypertension we investigated efficacy and tolerability of the new ACE-inhibitor Imidapril. Mean blood pressure at baseline was 172 +/- 19/98 +/- 10 mmHg. Treatment with Imidapril 5-20 mg once daily caused a decrease in BP by 21 +/- 17/11 +/- 10 mmHg

Step II treatment with labetalol for essential hypertension.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Labetalol, a new alpha- and beta-adrenergic blocking agent, was administered to 57 patients with essential hypertension whose standing diastolic blood pressure was 105 to 120 mm Hg after three and four weeks of placebo therapy and greater than 90 mm Hg after three to four weeks of therapy with

The use of minoxidil in the treatment of severe essential hypertension: a report on 100 patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. One hundred patients with severe essential hypertension have been treated with minoxidil for a mean period of 8-4 months in a study involving eleven European centres. Seventy-two males and twenty-eight females were included in the group; the mean age was 55 years and the initial supine systolic

Overview of clinical trials of dilevalol in essential hypertension.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The efficacy, tolerability and safety of dilevalol in essential hypertension has been documented in an international clinical trials programme which was conducted with doses up to 1600mg daily. Initial double-blind trials confirmed the superiority of dilevalol over placebo in essential hypertensive

Effects of the dopaminergic agonist cianergoline on blood pressure, the renin-angiotensin-aldosterone axis and the sympathetic nervous system in patients with essential hypertension.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Cianergoline is a new dopaminergic agonist with a predominant cardiovascular action. Its effects on blood pressure, the renin-angiotensin-aldosterone axis, the sympathetic nervous system and lipid metabolism were assessed in 20 patients with benign essential hypertension. Cianergoline given in

Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Ramipril is a newly synthesized angiotensin converting enzyme inhibitor without a sulfhydryl group in the molecule but with a prolonged duration of action. Efficacy, tolerance and safety of this drug were evaluated in 10 patients with severe essential hypertension. After a treatment period of at

A double-blind multicentre study of piretanide and hydrochlorothiazide in patients with essential hypertension.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In a randomized double-blind parallel group study conducted in three centres the hypotensive activity of piretanide 6 mg b.i.d. was compared with that of hydrochlorothiazide (HCT) 25 mg b.i.d. and HCT 50 mg b.i.d. Ninety-three patients entered the study and sixty-one completed a 16-week trial

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye